Navigation Links
Cetero Research Announces Completion of 20,000th Early-Phase Clinical Study

CARY, N.C., Jan. 27, 2011 /PRNewswire/ -- Cetero Research, the leading early-stage contract research organization (CRO), today announced that it has reached another industry milestone with the completion of its 20,000th early-phase clinical study. This achievement solidifies Cetero's position as the unmatched leader in early-phase clinical development and highlights the range of study experience and therapeutic expertise that Cetero offers to pharmaceutical, biotechnology and generic clients.

"We are very proud of this extraordinary accomplishment, which has been made possible by our dedicated staff and loyal clients," said Troy W. McCall, PhD, Chief Executive Officer of Cetero. "One of the best measures of a CRO's capabilities is its depth and breadth of experience. Cetero can offer clients more efficient clinical studies and assurance of high-quality data on time as a result of having more early-phase experience than any other CRO."  

In conducting 20,000 studies over the past 30 years, Cetero has developed considerable experience with normal healthy participants, special populations and patients. Through targeted recruitment strategies and a constantly updated database, Cetero currently delivers a 99 percent on-time recruitment rate.

"Twenty-thousand studies is a significant achievement and truly reflects Cetero's strengths in conducting both traditional clinical trials with normal healthy participants and specialty Phase I and IIa trials with patients," said Alan Copa, PharmD, President, Clinical Operations - Fargo of Cetero. "Cetero's expertise across a wide range of therapeutic areas provides us with insights on drug development strategies in addition to efficient study execution."

About Cetero Research

Cetero Research is the leading early-stage contract research organization (CRO). With nearly 30 years of experience from its founding companies, Cetero has conducted more than 20,000 clinical pharmacology studies - more than any other CRO. Cetero's proven track record allows the company to provide flexible and high-quality drug development services. The company's time-tested systems produce consistent and reliable data clients can trust. Cetero's clinical research expertise consists of traditional early-stage, normal healthy clinical pharmacology and bioavailability studies, as well as specialty Phase Ia/b trials in patients. Its bioanalytical services support clinical, preclinical drug and biomarker analysis for small and large molecules. For more information, visit, or call 877.7CETERO.

SOURCE Cetero Research
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cetero Research Names Dr. Roger Hayes President of Bioanalytical Operations
2. Cetero Research Launches Seminar Series on Accelerated Proof-of-Concept in Drug Development
3. Cetero Research Leads Industry in Human Allergy Models
4. Profil Institutes CEO Presenting on Early Phase Clinical Research in India
5. AndroScience Corporation Awarded a $3.8 Million, 3-Year Milestone-Driven, Cooperative Translational Research Grant from the NIH to Develop an Oral Treatment for Spinal Bulbar Muscular Atrophy (Kennedys Disease)
6. IRBNet Announces Release of National Research Network™ 2010 Benchmark Report
7. WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board
8. Octapharma Targets Primary Immune Deficiency Research With Grant for The Mount Sinai Medical Center
9. Independent Clinical Research Confirms Clinical Efficacy and Cost-Effectiveness of the SurgiCount Safety-Sponge® System
10. Best Practices, LLC Research Highlights Critical Role of Medical Affairs in New Product Launch Success
11. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
Post Your Comments:
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Surgical Procedure Volumes: Global Analysis (United States, ... Australia, Canada)" report to their offering. ... an essential tool for healthcare business planners, provides surgical ... looks at surgery trends with an in-depth analysis of ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/27/2016)... ... June 27, 2016 , ... A ... revolutionize the emergency ambulance transport experience for the millions of people who require ... has disrupted the taxi industry through the use of technology. Now, SmartEMS has ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
Breaking Medicine News(10 mins):